The proposed rule sought to ban rebates — the discounts drugmakers pay to pharmacy benefit managers — in Medicare and Medicaid, unless they are passed directly to the consumer at the pharmacy counter. The move could have upended the way the U.S. pays for drugs.
The proposed rule was one that the pharmaceutical industry supported, but the PBM and insurance industry fiercely opposed.
“Based on careful analysis and thorough consideration, the president has decided to withdraw the rebate rule,” White House spokesperson Judd Deere told The Hill.
HHS initially sought to ban these discounts on prescription drugs, arguing that the rebates PBMs and insurers negotiate with drugmakers are “back door deals” that have led to artificially high list prices.
Read the full report here.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
